Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad Shares to List on NYSE

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories said today that it intends to transfer its stock from the American Stock Exchange to the New York Stock Exchange on or around Oct. 24.
The firm’s Class A common stock will continue to trade under the ticker BIO, and its Class B common stock will continue to trade under the ticker BIOb.
Bio-Rad President and CEO Norman Schwartz said in a statement that the firm’s shareholders “will benefit from the NYSE’s brand, reputation, and trading efficiencies.”

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.